立体定向体部放疗治疗周围型T2N0M0非小细胞肺癌的I期研究(JCOG0702):PTV≥100cc组结果
本研究采用持续再评估法(CRM)对周围型T2N0M0非小细胞肺癌(NSCLC)患者进行SBRT剂量递增,以确定推荐剂量(RD)。
要点
- PTV≥100cc的周围型T2N0M0 NSCLC患者SBRT推荐剂量为50Gy/4次。
- 该组未观察到3级及以上放射性肺炎,2例出现2级放射性肺炎。
- 预测最大耐受剂量为50.2Gy,50Gy时2级RP频率超过40%的后验概率为5.3%。
核心结论
- 对于PTV≥100cc的周围型T2N0M0非小细胞肺癌患者,SBRT的推荐剂量确定为50Gy/4次。
研究设计与样本
- 本研究为I期剂量递增研究,采用持续再评估法(CRM)确定患者应接受的剂量水平并估计最大耐受剂量(MTD)。
- 剂量限制性毒性(DLT)定义为3级及以上放射性肺炎(RP),2级及以上RP作为替代DLT。
- 推荐剂量(RD)等于MTD,处方剂量规定在PTV的D95。
主要发现
- PTV≥100cc组中无患者发生3级放射性肺炎。
- 2例患者在50Gy/4次剂量水平发生2级放射性肺炎。
- 预测的最大耐受剂量(MTD)为50.2Gy。
- 在50Gy剂量水平,2级RP频率超过40%的后验概率为5.3%。
关键数值与推荐
- 推荐剂量(RD)确定为50Gy/4次。
- 剂量限制性毒性(DLT)为3级及以上放射性肺炎,2级及以上RP作为替代DLT。
- 处方剂量规定在PTV的D95。
临床怎么用
- 对于PTV≥100cc的周围型T2N0M0非小细胞肺癌患者,SBRT可采用50Gy/4次作为推荐剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A dose escalation study to determine the recommended dose (RD) with stereotactic body radiation therapy (SBRT) for peripheral T2N0M0 non-small cell carcinomas (NSCLC) was conducted. The results of the group with PTV⩾100cc are reported in this paper. MATERIALS AND METHODS: The continual reassessment method (CRM) was used to determine the dose level that patients should be assigned to and to estimate the maximum tolerated dose (MTD). Dose limiting toxicity (DLT) was Grade 3 or higher radiation pneumonitis (RP), and Grade 2 or higher RP was used as a surrogate DLT. The RD was equal to the MTD. The dose was prescribed at D95 of the PTV. RESULTS: Thirteen patients were accrued. More patients should have been enrolled but we decided not to prolong the study period. No patients experienced Grade 3 RP. Two patients experienced Grade 2 RP at 50Gy in 4 fractions. The predicted MTD was 50.2Gy. The posterior probability of the Grade 2 RP frequency over 40% was 5.3% for the dose level of 50Gy. The RD was determined to be 50Gy. CONCLUSIONS: The RD was determined to be 50Gy in 4 fractions in this population.
引用
- Onimaru R, Onishi H, Shibata T, et al. Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702): Results for the group with PTV⩾100cc. Radiother Oncol. 2016. PMID: 27993416. doi:10.1016/j.radonc.2016.11.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。